

REFERENCES

- About Us*. i3L (2022, June 29). Retrieved July 7, 2022, from <https://i3l.ac.id/about-us/>
- ANTARA News Banten. (2013, February 18). *Institusi pendidikan Bidang Farmasi i3l Segera Beroperasi*. ANTARA News Banten. Retrieved July 7, 2022, from <https://banten.antaranews.com/berita/18452/institusi-pendidikan-bidang-farmasi-i3l-segera-beroperasi>
- Addgene. (2017). Chapter 8: You've Made a Plasmid... Now What? In *Plasmids 101: A Desktop Resource* (3rd ed., pp. 155–181). essay, Addgene.
- Al-Hejin, A. M., Bora, R. S., & Ahmed, M. M. M. (2019). *Plasmids for optimizing expression of recombinant proteins in E. coli*. *Plasmid*, 13.
- Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003). *Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs*. *Science*, 300(5626), 1763-1767.
- Arya, R., Sabir, J. S., Bora, R. S., & Saini, K. S. (2015). *Optimization of culture parameters and novel strategies to improve protein solubility*. *Insoluble Proteins*, 45-63.
- Baca, A. M., & Hol, W. G. (2000). *Overcoming codon bias: a method for high-level overexpression of Plasmodium and other AT-rich parasite genes in Escherichia coli*. *International journal for parasitology*, 30(2), 113-118.
- Baranov, P. V., Henderson, C. M., Anderson, C. B., Gesteland, R. F., Atkins, J. F., & Howard, M. T. (2005). *Programmed ribosomal frameshifting in decoding the SARS-CoV genome*. *Virology*, 332(2), 498–510. <https://doi.org/10.1016/j.virol.2004.11.038>
- Bioinformatics*. i3L. (2022, June 15). Retrieved July 7, 2022, from <https://i3l.ac.id/programs-of-study/bioinformatics/>
- Bulut, C., & Kato, Y. (2020). *Epidemiology of COVID-19*. *Turkish journal of medical sciences*, 50(SI-1), 563-570.
- Bunnik, E. M., & Le Roch, K. G. (2013). An introduction to functional genomics and systems biology. *Advances in wound care*, 2(9), 490-498.
- Centers for Disease Control and Prevention. (2022, January 5). CDC Museum Covid-19 Timeline. Centers for Disease Control and Prevention. Retrieved January 20, 2022, from <https://www.cdc.gov/museum/timeline/covid19.html>
- Centers for Disease Control and Prevention. (n.d.). Management of patients with confirmed 2019-ncov. Centers for Disease Control and Prevention. Retrieved January 20, 2022, from <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html>

- Chan, J. F. W., Kok, K. H., Zhu, Z., Chu, H., To, K. K. W., Yuan, S., & Yuen, K. Y. (2020). *Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan*. *Emerging microbes & infections*, 9(1), 221-236.
- Chen, L., Liu, W., Zhang, Q., Xu, K., Ye, G., Wu, W., ... & Liu, Y. (2020). *RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak*. *Emerging microbes & infections*, 9(1), 313-319
- Chen, M. W., Cheng, T. J., Huang, Y., Jan, J. T., Ma, S. H., Yu, A. L., Wong, C. H., & Ho, D. D. (2008). *A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses*. *Proceedings of the National Academy of Sciences of the United States of America*, 105(36), 13538–13543. <https://doi.org/10.1073/pnas.0806901105>
- Davies, J., & Smith, D. I. (1978). *Plasmid-determined resistance to antimicrobial agents*. *Annual Reviews in Microbiology*, 32(1), 469-508.
- Dhar Chowdhury, S., & Oommen, A. M. (2020). *Epidemiology of COVID-19*. *Journal of Digestive Endoscopy*, 11(1), 3–7. <https://doi.org/10.1055/s-0040-1712187>
- Frediansyah, A., Nainu, F., Dhama, K., Mudatsir, M., & Harapan, H. (2021). *Remdesivir and its antiviral activity against COVID-19: A systematic review*. *Clinical epidemiology and global health*, 9, 123–127. <https://doi.org/10.1016/j.cegh.2020.07.011>
- Foster, T. J. (1983). *Plasmid-determined resistance to antimicrobial drugs and toxic metal ions in bacteria*. *Microbiological reviews*, 47(3), 361-409.
- Fu, H., Liang, Y., Zhong, X., Pan, Z., Huang, L., Zhang, H., ... & Liu, Z. (2020). *Codon optimization with deep learning to enhance protein expression*. *Scientific Reports*, 10(1), 1-9.
- Gu, J., & Korteweg, C. (2007). *Pathology and pathogenesis of severe acute respiratory syndrome*. *The American journal of pathology*, 170(4), 1136-1147.
- Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Zhong, N. S. (2020). *Clinical characteristics of coronavirus disease 2019 in China*. *New England journal of medicine*, 382(18), 1708-1720.
- Hartl, D. L., & Jones, E. W. (2001). *Genetics: analysis of genes and genomes*. Jones & Bartlett Learning.
- Huang, Y., Yang, C., Xu, X. F., Xu, W., & Liu, S. W. (2020). *Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19*. *Acta Pharmacologica Sinica*, 41(9), 1141-1149.
- Hussey C. (1992). *Recombinant plasmids*. *Safety in Industrial Microbiology and Biotechnology*, 93–152. <https://doi.org/10.1016/B978-0-7506-1105-3.50010-1>

- Huyan, T., Ruihua, T. A. N. G., Jing, L. I., Qi, L. I., Xiaoping, X. U. E., & Hui, Y. A. N. G. (2015). *Optimized expression and purification of humbug in Pichia pastoris and its monoclonal antibody preparation*. Iranian Journal of Public Health, 44(12), 1632.
- Ikemura, T. (1981). *Correlation between the abundance of Escherichia coli transfer RNAs and the occurrence of the respective codons in its protein genes: a proposal for a synonymous codon choice that is optimal for the E. coli translational system*. Journal of molecular biology, 151(3), 389-409
- Illumina, Inc. (2022). *Key differences between next-generation sequencing and Sanger sequencing: Understanding when NGS can be a more effective option*. NGS vs. Sanger Sequencing. Retrieved July 11, 2022, from <https://www.illumina.com/science/technology/next-generation-sequencing/ngs-vs-sanger-sequencing.html>
- Katella, K. (2021, December 20). *Omicron, Delta, Alpha, and more: What to know about the coronavirus variants*. Yale Medicine. Retrieved February 14, 2022, from <https://www.yalemedicine.org/news/covid-19-variants-of-concern-omicron>
- Kudla, G., Lipinski, L., Caffin, F., Helwak, A., & Zylicz, M. (2006). *High guanine and cytosine content increases mRNA levels in mammalian cells*. PLoS Biology, 4(6), 0933–0942. <https://doi.org/10.1371/journal.pbio.0040180>
- Lee, C. Y. P., Lin, R. T., Renia, L., & Ng, L. F. (2020). *Serological approaches for COVID-19: epidemiologic perspective on surveillance and control*. Frontiers in immunology, 11, 879.
- Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., ... & Feng, Z. (2020). *Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia*. New England journal of medicine.
- Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., ... Tan, W. (2020). *Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding*. Lancet (London, England), 395(10224), 565–574. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
- Lusiany, T. (2016). *KONSTRUKSI, DESAIN, DAN EKSPRESI PROTEIN P Domain TERINTEGRASI EPITOP HBsAg DAN EPITOP HBcAg PADA SEL Escherichia coli BL21(DE3) SEBAGAI KANDIDAT VAKSIN INTRANASAL HEPATITIS B*. (Bachelor Dissertation). Institut Teknologi Bandung, Bandung, Indonesia
- Macrogen Europe. (2022, March 4). *NGS or Sanger Sequencing: An easy guide for choosing the right technology*. Retrieved July 11, 2022, from <https://www.macrogen-europe.com/blog-news/ngs-or-sanger-sequencing-an-easy-guide-for-choosing-the-right-technology>

- Mason, R. J. (2020). *Pathogenesis of COVID-19 from a cell biology perspective*. European Respiratory Journal, 55(4).
- Men, A. E., Wilson, P., Siemering, K., & Forrest, S. (2008). *Sanger DNA sequencing*. Next Generation Genome Sequencing: Towards Personalized Medicine, 1-11.
- Morgan, K. (2020, November 11). *Plasmids 101: Origin of replication*. Addgene. Retrieved May 30, 2022, from <https://blog.addgene.org/plasmid-101-origin-of-replication>
- Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R. (2020). *Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV*. Chembiochem, 21(5), 730-738.
- Mody, V., Ho, J., Wills, S., Mawri, A., Lawson, L., Ebert, M. C., ... & Taval, S. (2021). *Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents*. Communications biology, 4(1), 1-10.
- Muhyiddin, M., & Nugroho, H. (2021). *A Year of Covid-19: A Long Road to Recovery and Acceleration of Indonesia's Development*. Jurnal Perencanaan Pembangunan: The Indonesian Journal of Development Planning, 5(1), 1-19.
- Needle, D., Lountos, G. T., & Waugh, D. S. (2015). *Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity*. Acta Crystallographica Section D: Biological Crystallography, 71(5), 1102-1111.
- New England Biolabs. (n.d.). *NEBuffer Activity/performance chart with restriction enzymes*. NEB. Retrieved May 22, 2022, from <https://www.neb.com/tools-and-resources/usage-guidelines/nebuffer-performance-chart-with-restriction-enzymes>
- New England Biolabs. (2022). *Star Activity*. NEB. Retrieved May 22, 2022, from <https://www.neb.sg/tools-and-resources/usage-guidelines/star-activity>
- Novagen. (2003). *pET system manual*. (10th ed., pp. 1–68). Retrieved from <http://lifeserv.bgu.ac.il/wb/zarivach/media/protocols/Novagen%20pET%20system%20manual.pdf>
- Novick, R. P. (1987). *Plasmid incompatibility*. Microbiological reviews, 51(4), 381-395.
- Our faculty*. i3l. (2022, July 5). Retrieved July 7, 2022, from <https://i3l.ac.id/our-faculty/#Bioinformatics>
- Parikesit, A. A., Harisna, A. H., Maulida, N. F. (2020). *Penapisan Senyawa Flavanoid dengan Protease SARS-CoV-2 3C-like sebagai Senyawa bioaktif bahan alam untuk COVID-19 (Proposal ID 8c8d7258-289f-445d-a09f-a219f5fb3296)*. Kementerian Riset dan Teknologi/Badan Riset dan Inovasi Nasional.

- Padhan, K., Parvez, M. K., & Al-Dosari, M. S. (2021). Comparative sequence analysis of SARS-CoV-2 suggests its high transmissibility and pathogenicity. *Future Virology*, 10.2217/fvl-2020-0204. <https://doi.org/10.2217/fvl-2020-0204>
- Qian, Z., Travanty, E. A., Oko, L., Edeen, K., Berglund, A., Wang, J., ... & Mason, R. J. (2013). *Innate immune response of human alveolar type ii cells infected with severe acute respiratory syndrome–coronavirus*. *American journal of respiratory cell and molecular biology*, 48(6), 742-748.
- Roy, A., Kucukural, A., & Zhang, Y. (2010). *I-TASSER: a unified platform for automated protein structure and function prediction*. *Nature protocols*, 5(4), 725-738.
- Sharp, P. M., & Li, W. H. (1987). *The codon adaptation index—a measure of directional synonymous codon usage bias, and its potential applications*. *Nucleic Acids Research*, 15(3), 1281–1295. <https://doi.org/10.1093/nar/15.3.1281>
- Silver, S., & Misra, T. K. (1988). *Plasmid-mediated heavy metal resistances*. *Annual Reviews in Microbiology*, 42(1), 717-743.
- Swanson, L. (2014, August 28). *Plasmids 101: How to verify your plasmid using a Restriction Digest analysis*. Addgene. Retrieved May 19, 2022, from <https://blog.addgene.org/plasmids-101-how-to-verify-your-plasmid>
- Ullrich, S., & Nitsche, C. (2020). The SARS-CoV-2 main protease as drug target. *Bioorganic & medicinal chemistry letters*, 30(17), 127377. <https://doi.org/10.1016/j.bmcl.2020.127377>
- Vahedi, F., Khatami, F., & Es-haghi, A. (2011). The stability of pET21+ PA, a pET derived plasmid, under different culture conditions. *World Journal of Microbiology and Biotechnology*, 27(2), 253-257.
- Van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., ... & Munster, V. J. (2020). *Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1*. *New England journal of medicine*, 382(16), 1564-1567.
- Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020). *Detection of SARS-CoV-2 in different types of clinical specimens*. *Jama*, 323(18), 1843-1844.
- What is Sanger sequencing?* Thermo Fisher Scientific - SG. (2022). Retrieved May 19, 2022, from <https://www.thermofisher.com/sg/en/home/life-science/sequencing/sequencing-learning-center/capillary-electrophoresis-information/what-is-sanger-sequencing.html>
- Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., ... & Wendtner, C. (2020). *Virological assessment of hospitalized patients with COVID-2019*. *Nature*, 581(7809), 465-469.

- World Health Organization. (n.d.). Indonesia: WHO coronavirus disease (covid-19) dashboard with vaccination data. World Health Organization. Retrieved January 20, 2022, from <https://covid19.who.int/region/searo/country/id>
- World Health Organization. (2020). Who statement on novel coronavirus in Thailand? World Health Organization. Retrieved February 16, 2022, from <https://www.who.int/news/item/13-01-2020-who-statement-on-novel-coronavirus-in-thailand>
- World Health Organization. (2020). Modes of transmission of virus causing COVID-19: Implications for IPC precaution recommendations. World Health Organization. Retrieved February 16, 2022, from <https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations>
- Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., ... & Wang, F. S. (2020). *Pathological findings of COVID-19 associated with acute respiratory distress syndrome*. *The Lancet respiratory medicine*, 8(4), 420-422.
- Zimmer, C. (2021, February 26). The secret life of a coronavirus. *The New York Times*. Retrieved January 20, 2022, from <https://www.nytimes.com/2021/02/26/opinion/sunday/coronavirus-alive-dead.html>